Per Bloomberg
Cathie Woods Slowly Accumulated Shares in Less Known Biopharmaceutical Company NRIX
10/20/2022
Cathie Woods' Ark Genomic Revolution ETF has been accumulating shares of a less-known biopharmaceutical company called Nurix Therapeutics Inc since October 10.
Woods started purchasing after NRIX shares dropped over 75% from its January 2021 record. The fund has accumulated 840,000 shares in the company with a market cap worth $518 million.
Ark has secured a top 15 shareholders spot in Nurix with an over 2.7% stake. The fund's medicine ETF is down 50% this year.
See full $NRIX flow at unusualwhales.com/flow.
The gap between what Americans earn and how much they need to bring in to achieve a basic standard of living is growing
5/30/2025 8:56 PMTrump: China violated its agreement with the US
5/30/2025 8:53 PMDuolingo, DUOL, CEO says AI is a better teacher than humans—but schools will still exist ‘because you still need childcare’
5/30/2025 8:51 PMCanada is entering a recession and will soon bleed another 100,000 jobs, TD chief economist has said
5/30/2025 8:50 PM
Stay Updated
Subscribe to our newsletter for the latest financial insights and news.
Unusual Whales does not confirm the information's truthfulness or accuracy of the associated references, data, and cannot verify any of the information. Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Options, investing, trading is risky, and losses are more expected than profits. Please do own research before investing. Please only subscribe after reading our full terms and understanding options and the market, and the inherent risks of trading. It is highly recommended not to trade on this, or any, information from Unusual Whales. Markets are risky, and you will likely lose some or all of your capital. Please check our terms for full details.
Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Certain investment planning tools available on Unusual Whales may provide general investment education based on your input. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your legal or tax professional regarding your specific situation. See terms for more information.